It would seem so, but that brings us around to your second question concerning measures. Let me recall something that my colleague from CIDA said earlier. What we're dealing with here is a facilitating regime. It allows the private sector -- we're not talking about a government program -- to take advantage of opportunities to sell and export at low cost to developing countries patented generic drugs. Now then, if there are no opportunities, if the countries... That doesn't affect the means. If the means do not exist, everything else is purely “academic”, in some respects.
In terms of level of involvement, I'll let my colleague from CIDA field that question.